Core Viewpoint - Baiyang Pharmaceutical's subsidiary plans to introduce a $4.9 million investment from Zap Therapeutic, enhancing collaboration in innovative medical devices and local production of the ZAP-X surgical robot [1] Group 1: Investment and Capital Structure - Baiyang Health's subsidiary, Hebei Baiyang Sap Medical Equipment Technology Co., Ltd., will increase its registered capital to $10 million following the investment [1] - Baiyang Health's ownership stake will decrease to 51% post-investment [1] Group 2: Strategic Collaboration - The investment aims to leverage both parties' resources, including funding, technology, and market channels [1] - Baiyang plans to invest in Zap Medical System, Ltd. starting July 2024, focusing on exclusive commercialization and manufacturing services for the ZAP-X surgical robot [1] Group 3: Market Impact - The collaboration is expected to facilitate the localization of ZAP-X production and expedite its integration into clinical settings [1]